Provided by Tiger Fintech (Singapore) Pte. Ltd.

DiaMedica Therapeutics Inc.

3.76
+0.19005.32%
Post-market: 3.60-0.1600-4.26%16:46 EDT
Volume:153.00K
Turnover:566.55K
Market Cap:161.24M
PE:-5.80
High:3.81
Open:3.57
Low:3.55
Close:3.57
Loading ...

DiaMedica Therapeutics Joins Russell 2000 and 3000 Indexes

Reuters
·
24 Jun

Lake Street Keeps Their Buy Rating on Diamedica Therapeutics (DMAC)

TIPRANKS
·
29 May

Diamedica Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
29 May

BRIEF-DiaMedica Therapeutics Announces Poster Presentation At European Stroke Organisation Conference – ESOC 2025

Reuters
·
15 May

DiaMedica Therapeutics Announces Poster Presentation at European Stroke Organisation Conference – Esoc 2025

THOMSON REUTERS
·
15 May

DiaMedica Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
14 May

BRIEF-DiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights

Reuters
·
14 May

DiaMedica Therapeutics Reports Increased Net Loss of $7.7 Million and Loss Per Share of $0.18 in Q1 2025

Reuters
·
14 May

DiaMedica Therapeutics- Topline Dm199 Phase 2 Part 1a Results Expected in Near Term and Phase 2 Part 1B Expected to Initiate in Q3 2025

THOMSON REUTERS
·
14 May

DiaMedica Therapeutics Inc: Cash Runway Into Q3 2026

THOMSON REUTERS
·
14 May

DiaMedica Therapeutics Inc expected to post a loss of 18 cents a share - Earnings Preview

Reuters
·
10 May

DiaMedica Therapeutics Inc expected to post a loss of 18 cents a share - Earnings Preview

Reuters
·
02 May

Diamedica Therapeutics (DMAC) Gets a Buy from Lake Street

TIPRANKS
·
19 Mar

DiaMedica Therapeutics Inc. : H.c. Wainwright Raises Target Price to $10 From $7

THOMSON REUTERS
·
19 Mar

DiaMedica Therapeutics Inc (DMAC) Q4 2024 Earnings Call Highlights: Strong Financial Position ...

GuruFocus.com
·
19 Mar

Q4 2024 DiaMedica Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents
·
19 Mar

DiaMedica Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
18 Mar

DiaMedica Therapeutics: Preeclampsia Phase 2 Trial Preliminary Topline Safety, Efficacy Data From Part 1a of Study Expected in Q2 2025

THOMSON REUTERS
·
18 Mar

Press Release: DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2024 Financial Results

Dow Jones
·
18 Mar

Insider Stock Buying Reaches US$9.00m On DiaMedica Therapeutics

Simply Wall St.
·
17 Mar